Equity Research Report: Dhanuka Agritech Limited
Date: February 7, 2026
Analyst: Gemini (Stock Analysis AI)
Current Market Price (CMP): ₹1,051 – ₹1,068 (Approx)
1️⃣ Business Model & Work
- Core Business: Dhanuka Agritech ek pure-play Agrochemical Company hai. Ye kisanon ke liye Herbicides (kharpatwar nashak), Insecticides (keed nashak), Fungicides, aur Plant Growth Regulators banati hai.
- Unique Strategy (Asset-Light): Unlike competitors jo technicals (raw material) khud banate hain, Dhanuka ka model “Brand & Distribution” par focus karta hai. Ye global innovators (Japan/USA) se technicals import karte hain, aur India me formulate karke apne brand name se bechte hain.
- Revenue Mix:
- Herbicides: ~37%
- Insecticides: ~28%
- Fungicides: ~21%
- Others: ~14%
- Competitive Advantage: Strong tie-ups with global giants like Nissan, Hokko, Oro Agri (Japan/USA). Inke paas exclusive rights hain kayi patented products bechne ke.
2️⃣ Industry & Sector Analysis
- Sector Status: Cyclical Headwind (Challenging Phase). Agrochemical sector pichle 1 saal se “Inventory Destocking” aur “Erratic Weather” se जूझ raha hai.
- Current Trend (2026):
- Weather Impact: FY26 me uneven rainfall (kahin sookha, kahin baadh) ne pest infestation kam kiya, jisse insecticides ki demand gir gayi.
- Price Pressure: China se cheap supplies ne prices ko crash kiya hai, jisse industry margins pressure me hain.
- Major Competitors: PI Industries, Bayer CropScience, UPL, Rallis India.
3️⃣ Latest Financial Performance (Q3 FY26 – Dec 2025)
⚠️ Data Source: Verified from Q3 FY26 Results (Announced Feb 5, 2026).
| Metric | Q3 FY26 (Dec ’25) | Q3 FY25 (Dec ’24) | YoY Change | Comment |
| Revenue | ₹409.9 Cr | ₹445.3 Cr | 🔻 7.9% | Volume decline due to weak season |
| EBITDA | ₹58.7 Cr | ₹75.6 Cr | 🔻 22.4% | Negative operating leverage |
| EBITDA Margin | 14.3% | 17.0% | 🔻 Dip | Lower sales impacted margins |
| Net Profit (PAT) | ₹40.0 Cr | ₹55.0 Cr | 🔻 27.3% | Sharp profit drop |
| EPS | ₹8.87 | ₹12.25 | 🔻 | Earnings hit this quarter |
Historical Trend (Last 5 Years – Revenue & PAT in ₹ Cr):
| Year | Revenue | Net Profit | Trend |
| FY25 | ₹2,035 Cr | ₹297 Cr | 🔼 Best Year |
| FY24 | ₹1,758 Cr | ₹239 Cr | 🔼 Steady |
| FY23 | ₹1,700 Cr | ₹233 Cr | ↔️ Flat |
| FY22 | ₹1,478 Cr | ₹208 Cr | 🔼 Growth |
| FY21 | ₹1,387 Cr | ₹210 Cr | ↔️ Base |
- Financial Health: Balance Sheet Zero Debt (Cash Rich) hai. Cash & Equivalents ~₹250 Cr+ hain jo downside protection dete hain.
4️⃣ Management & Shareholding (Latest – Dec 2025)
| Category | Holding (%) | Observation |
| Promoters | 69.71% | Very High & Stable. Agarwal/Dhanuka family ka control strong hai. |
| FIIs | 2.13% | Slightly decreased (-0.17%). Foreign interest low hai. |
| DIIs / Mutual Funds | 18.81% | High Confidence (+1.3% Increase). DSP Small Cap, HDFC Midcap, aur Kotak Small Cap ne stake badhaya hai despite bad results. |
| Public | 9.37% | Retail holding kam hai, jo stock price stability ke liye achha hai. |
- Governance: Management (Mahendra Kumar Dhanuka, Rahul Dhanuka) ka track record shareholder-friendly hai. Regular buybacks (last in 2024) aur dividends (Yield ~1.5%) inka hallmark hai.
5️⃣ Valuation (Latest Market Data)
- Current P/E (TTM): ~17x – 18x.
- 5-Year Avg P/E: ~20x. (Stock abhi apne historical average se Sasta mil raha hai).
- Peer Comparison:
- PI Industries: ~35x P/E (Premium due to CSM business).
- Bayer CropScience: ~30x P/E.
- Rallis India: ~28x P/E.
- Dhanuka: ~17x P/E.
- Fair Value View: Dhanuka apne peers ke mukable “Significantly Undervalued” hai. Market ne short-term weather issues ko zyada penalize kiya hai.
6️⃣ Future Growth Triggers (3–5 Years)
- Dahej Plant Expansion: Dhanuka ne pehli baar technical manufacturing (backward integration) me entry li hai. Dahej plant se naye molecules (Bifenthrin, Lambda) ka production FY27 se full swing me aayega, jo margins sudharega.
- New Product Launches: Company ne FY26 me LaNevo, MYCORe SUPER, Purge jaise naye products launch kiye hain. Naye products ka contribution revenue me ~16% hai, jo healthy innovation dikhata hai.
- Biologicals Segment: Dhanuka “BiologiQ” range ke zariye bio-pesticides me aggressive ho raha hai, jo future farming ka trend hai.
7️⃣ Present Situation & Outlook
- Stock Trend: Q3 results (Feb 5) ke baad stock ne thoda correction dikhaya hai, lekin ₹1,000 – ₹1,020 ke aas-paas strong support le raha hai.
- Short-Term (Painful): Q4 (Jan-Mar) bhi weak rehne ki ummeed hai kyunki inventory level abhi bhi high hai. Sentiment negative rahega.
- Long-Term (Opportunity): Jaise hi monsoon normal hoga (FY27 forecast), Dhanuka sabse pehle recover karega kyunki iska balance sheet lean hai aur inventory manageable hai.
8️⃣ Risk & Red Flags
- Monsoon Dependency: Dhanuka ka 100% business agriculture par hai. Kharab monsoon = Kharab Sales.
- Regulatory Risk: Sarkar kabhi bhi kuch chemicals (jaise Glyphosate) ban kar sakti hai, jisse revenue par asar padta hai.
- Raw Material Prices: China se raw material supply disrupt hone par margins gir sakte hain (jaisa Q3 me hua).
9️⃣ Final Verdict
- Summary: Dhanuka Agritech ek “Quality Stock in Trouble” hai. Company me koi internal kharabi nahi hai, sirf external mahaul (weather/industry cycle) kharab hai.
- For Conservative Investors: SIP START. Ye stock volatility dikhayega, lekin 3-5 saal ke liye ye ek safe bet hai (Zero Debt + High Promoter Holding).
- For Aggressive Investors: BUY ON DIPS. Current valuation (17x PE) par downside limited hai. Jab cycle turn hogi (likely H2 FY27), ye stock 25x PE tak re-rate ho sakta hai.
- Target Range: FY27 Recovery ke basis par ₹1,400 – ₹1,500 ka target 18-24 mahine me reasonable lagta hai.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.